Literature DB >> 10195879

Development and application of adenoviral vectors for gene therapy of cancer.

W W Zhang1.   

Abstract

For successful gene vaccination and therapy of cancer, it is essential to develop gene delivery vectors that can meet clinical and social requirements. The need for improved vectors was clearly manifested during the peak of the first wave of gene therapy. Adenoviral (Ad) vectors have recently drawn the attention of many of those involved in the field of gene therapy for cancer because of their practical advantages and application potential. Many experiments, innovations, preclinical studies, and clinical trials have generated an overwhelming amount of data and literature concerning this vector system. It is hoped that the comprehensive review presented here, which includes the principles, potential, capacity, and limitations of the current Ad systems, will help to further the rational development of the system. The literature in this article is organized in an attempt to emphasize Ad vector development in the aspects of technical approaches, practical hurdles and strategies to overcome them, significant experimental results, recent advances, future directions, etc. The technical range of this review covers details that are intended to serve as a reference for advanced technical readers and provide a foundation for initiates in the field of Ad vector gene therapy. The material presented here is also intended for nontechnical persons who want to have an overview of the significance and potential of the technology.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195879     DOI: 10.1038/sj.cgt.7700024

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  21 in total

Review 1.  Gene therapy for liver diseases: recent strategies for treatment of viral hepatitis and liver malignancies.

Authors:  V Schmitz; C Qian; J Ruiz; B Sangro; I Melero; G Mazzolini; I Narvaiza; J Prieto
Journal:  Gut       Date:  2002-01       Impact factor: 23.059

2.  Inhibition of adenovirus-mediated p27kip1 gene on growth of esophageal carcinoma cell strain.

Authors:  Qing-Ming Wu; Jie-Ping Yu; Qiang Tong; Xiao-Hu Wang; Guo-Jian Xie
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 3.  The promise of gene therapy in gastrointestinal and liver diseases.

Authors:  J Prieto; M Herraiz; B Sangro; C Qian; G Mazzolini; I Melero; J Ruiz
Journal:  Gut       Date:  2003-05       Impact factor: 23.059

4.  Magnetic nanoparticles enhance adenovirus transduction in vitro and in vivo.

Authors:  Cédric Sapet; Christophe Pellegrino; Nicolas Laurent; Flavie Sicard; Olivier Zelphati
Journal:  Pharm Res       Date:  2011-12-07       Impact factor: 4.200

Review 5.  Cancer immunotherapy: a paradigm shift for prostate cancer treatment.

Authors:  Dev Karan; Jeffrey M Holzbeierlein; Peter Van Veldhuizen; J Brantley Thrasher
Journal:  Nat Rev Urol       Date:  2012-05-29       Impact factor: 14.432

6.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

7.  Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo.

Authors:  C Cubillos-Zapata; E Guzman; A Turner; S C Gilbert; H Prentice; J C Hope; B Charleston
Journal:  J Virol       Date:  2011-07-13       Impact factor: 5.103

Review 8.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show?

Authors:  Stefan Kaluz; Milota Kaluzová; Shu-Yuan Liao; Michael Lerman; Eric J Stanbridge
Journal:  Biochim Biophys Acta       Date:  2009-01-22

Review 9.  Gene therapy: regulations, ethics and its practicalities in liver disease.

Authors:  Xi Jin; Yi-Da Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2008-04-21       Impact factor: 5.742

Review 10.  Vectorology and factor delivery in induced pluripotent stem cell reprogramming.

Authors:  Kejin Hu
Journal:  Stem Cells Dev       Date:  2014-04-16       Impact factor: 3.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.